A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease
about
Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasiaObstructing toxin pathways by targeted pore blockageMesenchymal stem cells as a vector for the inflammatory prostate microenvironmentQuantification of mineralized bone response to prostate cancer by noninvasive in vivo microCT and non-destructive ex vivo microCT and DXA in a mouse model.Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin.Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer.Channel-forming bacterial toxins in biosensing and macromolecule deliveryStructural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitorsEnzymatically active prostate-specific antigen promotes growth of human prostate cancers.Applications of biological pores in nanomedicine, sensing, and nanoelectronicsTargeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxinNew medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectivesPhospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF).Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden.A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases.Tumour endoproteases: the cutting edge of cancer drug delivery?Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia.Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.Development of peptides specifically modulating the activity of KLK2 and KLK3.Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer.Emerging treatment options for benign prostatic obstruction.Treatment of lower urinary tract symptoms: agents for intraprostatic injection.Investigational therapies targeted to the treatment of benign prostatic hyperplasia.Targeting kallikrein-related peptidases in prostate cancer.Targeted prodrug approaches for hormone refractory prostate cancer.Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.New intraprostatic injectables and prostatic urethral lift for male LUTS.Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.Protease-activated pore-forming peptides for the treatment and imaging of prostate cancerKLK-targeted Therapies for Prostate Cancer.A chimera of interleukin 2 and a binding variant of aerolysin is selectively toxic to cells displaying the interleukin 2 receptor.Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate.Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid.Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer.Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen.Mutational Analysis of Prostate-Specific Antigen Defines the Intrinsic Proteolytic Activity of the proPSA Zymogen.PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancer.Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise
P2860
Q24594742-F1BD26EC-98AA-407F-A6B4-A7342EBE140BQ26827489-837F49CA-C837-4C1F-910A-5B4F17E64C84Q26853374-A0AEFF41-9208-4D04-8D58-8AA65726F210Q33548724-46186B5D-8BB2-4447-BC93-B8F3E9A5AD88Q33927058-7C2EA1C9-3260-4785-AB6A-E621AA517462Q34037014-F9F8A835-A134-46A9-B3FB-A2B6EEDCE62BQ34101821-47BAC154-1434-40BD-B0CB-B863051E1236Q34732727-773C6852-C074-4AD9-B7FC-13D1255E81C5Q35048230-0066E314-3748-4140-9D25-190A984ACD9BQ35063550-2BAE7637-7192-43C8-95A1-1280FA6CBC93Q35947656-EBAD92C4-B02D-4E95-A74C-73E6D8CB6E78Q36133212-6976C65F-9452-4F05-8903-1EA46D7D4F73Q36243031-5D78E841-92F5-4018-8A96-AC63A64A38CBQ36266738-52BDB0CF-960E-4D2B-B5C7-23894CCA9090Q36545204-4E204D9D-8B84-42C9-98C6-E0CCDAB516C0Q36776738-144C8FB9-113C-4F04-9008-E5FE29F5D904Q36920121-091E5CF5-5864-4EC3-A130-7A8A95FD059EQ37060284-1F031A38-31B1-4F39-9E26-7F8822B7CEA8Q37088315-9809163F-1A98-42AF-B3D1-B4965FA88215Q37133208-D165C19E-082D-488D-832C-EA43CA25B9B9Q37216674-FAAD706A-72FA-4CE8-9E5E-474EC610C40AQ37697815-B3C61236-1F73-4AD0-B0DD-513F8D8FC4B7Q37863036-3847AA64-8722-4B9A-9ED6-8F7A81433F5AQ38071100-DB4C1D12-7005-4043-B99E-B737B87410B7Q38073830-4E751078-BAAF-473D-9A11-488B432E1A67Q38191293-7D0754EF-7582-4724-AC80-8FFFDAFECEB4Q38295983-A80D721C-46D8-4AD6-AA8E-9408DC5749B3Q38413737-891A6728-4FC6-41D1-92A8-C781F1318C80Q38551294-821FCD91-9A8A-4EC9-AC68-4894C660A2DAQ38760061-2BE61BC4-CA5C-490B-AF6C-B2456274B8E9Q38925667-077F22E5-8185-4DC1-BABD-F694A81456C9Q38967486-064F0FE6-A1C1-4E79-9B7A-D6057EF98F27Q40056988-A59F1630-06F5-4248-A89E-A5FCFFACEC67Q41470722-C4674EA8-2A92-44EF-AEC4-0A3253EF2F59Q41860731-8D4E17E6-A448-4843-B928-2E30EF5FF1EAQ42072059-86405FC5-0868-47CB-86F2-6E4DECDEE9ECQ42177972-806CC110-B3BE-498A-A4F7-8E175DF8015EQ51714928-3277B5CF-D025-4E82-91C6-EA93B510F4A9Q55018508-E39A27BE-755C-4193-8E99-C6C250B0D547Q58804653-35C7ACEB-CCFE-4EF0-8040-C42AD3BD4BF8
P2860
A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A prostate-specific antigen-ac ...... therapy for prostatic disease
@ast
A prostate-specific antigen-ac ...... therapy for prostatic disease
@en
A prostate-specific antigen-ac ...... therapy for prostatic disease
@nl
type
label
A prostate-specific antigen-ac ...... therapy for prostatic disease
@ast
A prostate-specific antigen-ac ...... therapy for prostatic disease
@en
A prostate-specific antigen-ac ...... therapy for prostatic disease
@nl
prefLabel
A prostate-specific antigen-ac ...... therapy for prostatic disease
@ast
A prostate-specific antigen-ac ...... therapy for prostatic disease
@en
A prostate-specific antigen-ac ...... therapy for prostatic disease
@nl
P2093
P2860
P356
P1476
A prostate-specific antigen-ac ...... therapy for prostatic disease
@en
P2093
Elizabeth Garrett-Mayer
J Thomas Buckley
John T Isaacs
Rosemina F Merchant
Samuel R Denmeade
Simon A Williams
P2860
P304
P356
10.1093/JNCI/DJK065
P407
P577
2007-03-01T00:00:00Z